



The Canadian Association for Population Therapeutics /
Association Canadienne pour la Thérapeutique des Populations

presents:

**“A Look to the Future:
Medication Use, Safety and Effectiveness
under Economic Uncertainty”**

PROGRAM

April 19th - 21st, 2009
Montreal, Quebec
Fairmont The Queen Elizabeth

(Inside Front Cover)

CAPT MISSION & VISION

The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

CAPT 2009 SCIENTIFIC & ORGANIZING COMMITTEE:

Lori-Jean Manness, Merck Frosst Canada Ltd.

Colleen Metge, University of Manitoba

Nicole Mittmann, Sunnybrook and Women's College HSC

Nigel Rawson (Chair), GlaxoSmithKline Canada & CAPT President-elect

Angela Rocchi, Axia Research

Kris Schindel, CAPT Secretariat

Judith Soon, University of British Columbia and CAPT President

Message from the President

We are pleased that you have joined Canadian academic researchers, federal and provincial policy-makers, pharmaceutical industry representatives and other experts at the annual Canadian Association for Population Therapeutics conference being held on April 19 - 21, 2009 at the Fairmont The Queen Elizabeth Hotel in Montreal, QC.

This past year has been an exciting one for CAPT, as Board members undertook a Strategic Planning Initiative, as well as a survey of the membership and interviews with key stakeholders. This process has not only facilitated the development of a new mission and vision for our association, but also has re-invigorated the valuable legacy of the CAPT Annual Conference. Over the next few days, enjoy meeting experts from across Canada as you listen to provocative presentations, peruse the posters, and are entertained at dinner with the *Magic of the Big Top!*

Judith Soon
CAPT President

CAPT 2009 Conference Overview

Welcome to the 2009 CAPT/ACTP conference! The title of this year's conference, "A Look to the Future: Medication Use, Safety and Effectiveness under Economic Uncertainty" is highly relevant as governments and societies attempt to keep their heads above the surface of the current economic quagmire. The Program Committee offers its sincere thanks to the conference sponsors in these difficult times.

The mission of CAPT/ACTP is to advance population-based research of therapeutic interventions to improve the health of Canadians by bringing together diverse perspectives, facilitating open exchange of ideas and collaboration, and influencing policy and practice. The Scientific Committee has designed the conference program to achieve this mission by inviting a wide variety of keynote speakers and panelists, by including more panel sessions than in previous conferences, and by having a focus on policy. In addition, we have many exciting contributed presentations and posters. I encourage you to maximize your opportunities for interaction and exchange of ideas throughout the three days with both old and new colleagues and friends, and hope that you enjoy the conference.

Nigel Rawson
Chair, Scientific Committee

A Look to the Future: Medication Use, Safety and Effectiveness under Economic Uncertainty

Saturday, April 18th, 2009

18:00 **CAPT Board of Directors Meeting**
Location: Richelieu Room

Sunday, April 19th, 2009

09:00 – 17:00 **Registration**

Satellite Symposium

Location: Duluth/Mackenzie Room

10:30 – 12:00 **Paladin Satellite Symposium (Pre-registration required)**
Putting the patient at the centre of care:
Health professionals helping out with “intelligent adherence”
Chair: Colleen Metge, University of Manitoba

Soubhi Hassan, Department of Family Medicine, Université de Sherbrooke
Yola Moride, Faculty of Pharmacy, Université de Montréal
Reza Alizadehfar, McGill University Health Centre

12:00 – 13:00 **Lunch (Foyer) (Sponsored by Paladin Labs)**
(All Conference Attendees Welcome)

Conference Commencement

Location: Duluth/Mackenzie Room

13:00 – 13:15 **Opening Remarks & Welcome**
Judith Soon, University of British Columbia, and President, Canadian
Association for Population Therapeutics

13:15 – 16:00 **Health Policy Symposium (Sponsored by Merck Frosst Canada Ltd.)**

Drug policy and decision making in uncertain times

Stuart MacLeod (Chair), Executive Director, Child & Family Research
Institute, University of British Columbia

Optimal therapeutics in the cauldron of uncertainty

Neil MacKinnon, Associate Director, Research & Associate Professor,
College of Pharmacy, Dalhousie University

Current controversies in Canadian drug policy

Olaf Koester, Director, Drug Management Policy Unit, Manitoba Health and Healthy Living

Utilization Management Agreements: a new policy direction

Karen Philp, Consultant – Patient Advocacy

Putting what really matters to patients into the heart of health policy: the key to sustainability of our healthcare system

Dawn Graham, President, Merck Frosst Canada; Chair, Canada's Research-Based Pharmaceutical Companies (Rx&D)

Access to innovative pharmaceuticals: moving from the yes/no imperative to how

16:00 – 16:30

Break (Foyer)

16:30 – 17:30

Contributed Oral Presentations

Chair: Lori-Jean Manness, Merck Frosst Canada

Oncology drugs in non-small cell lung cancer treatment: actual utilization versus treatment guidelines

V Giroux, Brogan Inc. (Abstract 13)

Illegal use of prescription drugs prior to the implementation of a province-wide Pharmacy Network

K Collins, Newfoundland and Labrador Centre for Health Information (Abstract 10)

A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: TEAM study

L Lalonde, University of Montreal (Abstract 1)

Factors associated with taking antihypertensives – a population-based cross-sectional study of hypertensive patients in the Canadian Community Health Survey

K Grindrod, University of British Columbia (Abstract 8)

17:30 – 19:00

Reception & Contributed Poster Presentations (Sponsored by AstraZeneca)

Location: Hochelaga 3 to 6

**** All Posters displayed from 12:00 h Sunday until Monday at 17:30 h in Hochelaga 3 to 6****

Monday, April 20th, 2009

07:30 – 17:00

Registration

07:30 – 08:30

Breakfast (Foyer) (Sponsored by Sanofi-Aventis)

Location: Duluth/Mackenzie Room

08:30 – 10:00

Pharmacoepidemiology

Chair: Allan Gillman, IMS Health

Keynote Speaker:

Steve Morgan, Associate Professor and Associate Director, Centre for Health Services and Policy Research, University of British Columbia

The Blockbuster Sunset: what changes in the primary care pharmaceutical market mean for research and policy

CAPT Contributed Oral Presentations

Macrolide-induced digoxin toxicity: a population-based study

T Gomes, Institute for Clinical Evaluative Sciences (Abstract 12)

Fracture risk from cardiovascular medications: a population-based analysis

CJ Metge, University of Manitoba (Abstract 9)

Impact of missing data on potential confounders in perinatal pharmacoepidemiologic studies using administrative databases

A Berard, University of Montreal and CHU Ste-Justine (Abstract 11)

10:00 – 10:30

Break & Contributed Poster Presentations (Sponsored by CADTH)

Location: Hochelaga 3 to 6

10:30 – 12:00

Pharmacoeconomics

Chair: Christopher Longo, McMaster University

Keynote Speaker:

Jeffrey Hoch, Associate Professor, University of Toronto, St. Michael's Hospital Centre for Research on Inner City Health

Frankenstein, Dracula and net benefit regression: what you need to know

CAPT Contributed Oral Presentations

Economic evaluation of rivaroxaban vs. enoxaparin in Canadian patients undergoing total hip replacement (THR) and total knee replacement (TKR)

H McDonald, Bayer Inc. (Abstract 6)

The monetary value of a genetic test for muscular adverse events induced by statins

E Martin, CRCHUM (Abstract 15)

Validity of a model mapping quality of life scores to utility scores in lymphoma

N Mittmann, HOPE Research Centre (Abstract 17)

- 12:00 – 13:30** **Buffet Lunch (Sponsored by Pfizer) & CAPT Annual General Meeting**
All Conference Attendees are Encouraged to Participate
- 13:30 – 14:30** **e-Prescribing: Opportunities and Directions**
Chair: Rolf Sebaldt, Clinforma
- Keynote Speaker:
Robyn Tamblyn, Professor, Departments of Medicine, and Epidemiology
and Biostatistics, McGill University
**Computerization of prescribing, dispensing & drug management:
New opportunities to improve the safety and effectiveness of drug
management**
- CAPT Contributed Oral Presentation**
- ePrescribing: current state, perceived benefits and barriers**
A Holbrook, McMaster University and St. Joseph's Healthcare (Abstract 7)
- 14:30 – 15:00** **Break & Contributed Poster Presentations (Sponsored by CADTH)**
Location: Hochelaga 3 to 6
- 15:00 – 17:15** **Health Policy Symposium (Sponsored by GlaxoSmithKline)**
Chair: Colleen Metge, University of Manitoba
- Incorporating social values into drug reimbursement decision-
making: Perspectives from the provinces, the public and the press**
- Beth Kapusta, Health care activist
Regis Blais, Lay member, Conseil du Medicament du Quebec
Ana Johnson, Member, Ontario Health Technology Advisory Committee
Ghislaine Cleret de Langavant, Quebec Deputy Health Commissioner for
Ethics
André Picard, Health reporter, Globe & Mail
- 19:00** **Social Event: CAPT Conference Dinner (Ticket Required)**
Reconnect with the CAPT Community Under The Magic of the Big Top!
Location: Salon Saint-Francois

Tuesday, April 21st, 2009

- 07:30 – 12:00** **Registration**
- 07:30 – 08:30** **Breakfast (Foyer)**
(Sponsored by Novo Nordisk Canada Inc.)

CONCURRENT SESSIONS #1 & #2

Session #1

Location: Duluth/Mackenzie Room

08:30 – 10:00

Hot Topic

Chair: John Sproule, Institute of Health Economics

CEDAC/CDR: Past learnings, future directions

Angela Rocchi, Principal, Axia Research
Robert Peterson, Chair, Canadian Expert Drug Advisory Committee
Frédéric Lavoie, Director, Patient Access, Pfizer Canada
Brian O'Rourke, Vice President, Common Drug Review

Session #2

Location: Hochelaga 6 Room

08:30 – 10:00

Contributed Oral Presentations

Chair: Carlo Marra, University of British Columbia

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

LY Park-Wyllie, St. Michael's Hospital / ICES (Abstract 4)

Patient preferences towards the clinical adoption of pharmacogenomics: a discrete choice experiment and implications for health policy

AM Issa, University of Houston (Abstract 14)

Case series as a tool for therapeutic risk management: a review of the literature

CN Abou Chakra, University of Montreal (Abstract 3)

Antidepressant medication use during pregnancy and the risk of miscarriage

HR Nakhai-Pour, University of Montreal and CHU Ste-Justine (Abstract 2)

Comparison of sleep quality between benzodiazepine users and non-users

SG Beland, University of Montreal (Abstract 5)

The unintended effects of prescription contraception: experiences of youth in northern British Columbia

JA Soon, University of British Columbia (Abstract 16)

10:00 – 10:30

Break (Foyer)

Location: Duluth/Mackenzie Room

10:30 – 12:00

Hot Topic

Chair: Denis Belanger, Canadian Agency for Drugs and Technologies in Health

Drug Safety and Effectiveness Network

Diane Forbes, Associate Director, Drug Safety and Effectiveness Network, Canadian Institutes of Health Research

Judith Glennie, Director, Submissions/Post-Marketing Effectiveness Research, Planning, Medical and Government Affairs Division, Janssen-Ortho

Olaf Koester, Director, Drug Management Policy Unit, Manitoba Health and Healthy Living

Cynthia Sunstrum, DSEN Project Manager, Office of Pharmaceuticals Management Strategies, Health Canada

Ingrid Sketris, Professor, College of Pharmacy, Dalhousie University

12:00 – 12:30

CAPT Awards Ceremony / Conference Close

Chair: Nigel Rawson, GlaxoSmithKline

12:30

Brown Bag Lunch

ORAL PRESENTATIONS

(Note: Presenting Authors are underlined)

1 – ENCORE PRESENTATION

Lalonde L, Villeneuve J, Genest J, Blais L, Vanier MC, Lamarre D, Fredette M, Lussier MT, Perreault S, Hudon E, Berbiche D **A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: TEAM study**

2

Nakhai-Pour HR, Broy P, Berard A **Antidepressant medication use during pregnancy and the risk of miscarriage**

3

Pariante A, Abou Chakra C N, Pinet M, Moore N, Moride Y **Case series as a tool for therapeutic risk management: a review of the literature**

4

Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN **Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study**

5

Beland SG, Preville M, Dubois MF, Bosse C, Voyer P, Perodeau G, Berbiche D, Moride, Y **Comparison of sleep quality between benzodiazepine users and non-users**

6

Wells P, Diamantopoulos A, McDonald H, Forster F, Lees M **Economic evaluation of rivaroxaban vs. enoxaparin in Canadian patients undergoing total hip replacement (THR) and total knee replacement (TKR)**

7

Holbrook A, Hasham S, Keshavjee K, Troyan S **ePrescribing: current state, perceived benefits and barriers**

8

Grindrod K, Colley L, Marra C, Lynd L, Koehoorn M **Factors associated with taking antihypertensives – a population-based cross-sectional study of hypertensive patients in the Canadian Community Health Survey**

9

Metge CJ, Prior H, Lix L, Leslie WD **Fracture risk from cardiovascular medications: a population-based analysis**

10

Collins K, MacDonald D, El-Aneed A, Donnan J, Gladney N, Bonia K **Illegal use of prescription drugs prior to the implementation of a province-wide Pharmacy Network**

11

Berard A, Nakhai-Pour HR, Kulaga S **Impact of missing data on potential confounders in perinatal pharmacoepidemiologic studies using administrative databases**

12

Gomes T, Juurlink DN, Mamdani MM **Macrolide-induced digoxin toxicity: a population-based study**

13

Giroux V **Oncology drugs in non-small cell lung cancer treatment: actual utilization versus treatment guidelines**

14

Issa AM, Tufail W, Hutchinson J, Baliga MP, Tenorio J **Patient preferences towards the clinical adoption of pharmacogenomics: a discrete choice experiment and implications for health policy**

15

Martin E, Sheehy O, LeLorier J **The monetary value of a genetic test for muscular adverse events induced by statins**

16

Soon JA, Shoveller JA, Reade J **The unintended effects of prescription contraception: experiences of youth in northern British Columbia**

17

Isogai P, Cheung M, Lathia N, Leigh N, Mittmann N, Working Group on Economic Analysis, NCIC CTG **Validity of a model mapping quality of life scores to utility scores in lymphoma**

POSTER PRESENTATIONS

18

Norrie O, Metge C **A stakeholder analysis of consumers' and pharmacists' willingness to accept and provide enhanced pharmacist services: a use of mixed methods to inform on policy implementation**

19 – ENCORE PRESENTATION

Selby R, Borah B, McDonald H, Henk J, Crowther M, Wells P **Alignment to prophylaxis guidelines and occurrence of venous thromboembolism after total hip and knee replacement**

20

Selby R, Becker D, McDonald H, Cartier S, Crowther M, Wells P **Burden of illness of venous thromboembolism following total hip and total knee replacement in Canada**

21

Nakhai-Pour HR, Rey E, Berard A **Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns**

22

Kulaga S, Sheehy O, Broy P, Bérard A **Benzodiazepine use during pregnancy and the risk of major congenital malformations**

23

Beard K, Folia C, Ferreira L **Calcium-based phosphate binders lead to increased progression of vascular calcification in chronic kidney disease**

24

Farahani P **Clinical bio-equivalent doses versus milligram-equivalent doses of therapeutics for pharmacoeconomic models**

25

Farahani P **Essentials of incorporating escalating doses (up-titration) of therapeutics in pharmaco-economic models**

26

Béland SG, Pariente A, Tournier M, Lebeau M, Galbaud Du Fort G, Crott R, Ducruet T, Moride Y **Cost-effectiveness of antidepressants in the adult patient population of Quebec: persistence as an indicator of effectiveness**

27

Béland SG, Pariente A, Berbiche D, Preville M, Moride Y **Impact of frailty on risk management strategies in the elderly population: psychotropic medications as a case study**

28

Rey E, David M, Gauthier R, Leduc L, Michon N, Morin F **Costs analysis of the prevention of severe preeclampsia/fetal restriction by dalteparin**

29

Wiercioch W, Holbrook A, Folia C, Millar D, Noronha R **Critical appraisal of the development and validation of adverse drug event indicators**

30

Koné Péfoyo AJ, Rivard M, Laurier C **Déterminants des variations géographiques de l'usage des médicaments d'asthme au Québec**

31

Koné Péfoyo AJ, Laurier C, Rivard M **Small-area variations in asthma medication**

32

Li KK, Holbrook A, Thabane L, Zardasht G, Teo K, Cook R **Determining the minimal clinically important difference for important outcomes of statin therapy**

33 – ENCORE PRESENTATION

Bernatsky S, Paterson M, Bhamani A, the Ontario Biologics Research Initiative **Disease-modifying anti-rheumatic drug (DMARD) exposures and serious infections in seniors with rheumatoid arthritis (RA): a nested case-control study**

34 – ENCORE PRESENTATION

Bernatsky S, Paterson M, Bhamani A, the Ontario Biologics Research Initiative **Tuberculosis (TB) in a population-based cohort of seniors with rheumatoid arthritis (RA)**

35 – ENCORE PRESENTATION

Bernatsky S, Paterson M, Hux J, Bombardier C, the Ontario Biologics Research Initiative **Use of administrative data to determine the potential effects of a national consensus statement on optimal early rheumatoid arthritis (RA) treatment in persons >65**

36 – ENCORE PRESENTATION

Paterson M, Bombardier C, Bernatsky S, Zagorski B, the Ontario Biologics Research Initiative **Utilization of biologic response modifying drugs (BRMs) by Ontario rheumatology specialists**

37

Clayton N, Oremus M, Tarride J-E, Raina P **Does the Canadian general public support an increase in annual taxes to provide access to an Alzheimer's disease medication?**

38

Wiercioch W, Holbrook A, Troyan S, Pullenayegum E, Foster G **Drug-related problems in patients with vascular risks**

39

Woolcott JC, Khan KM, Abu-Laban RB, Lillies B, Marra CA **Emergency department experiences of senior fallers: an operations research analysis**

40

Santos E, Bérard A **Exposure to anti-infective drugs during pregnancy and the risk of prematurity**

41

Moussally K, Koren G, Berard A **Exposure to herbal products during pregnancy and the risk of low birth weight**

42

Berard A, St-Andre M **Fluoxetine use during pregnancy and the risk of major congenital malformations**

43

WITHDRAWN

44

Broy P, Bérard A **Gestational exposure to antidepressants and the risk of miscarriage: a review**

45

Goetghebeur M, Khoury H, Wagner M, Rindress D, Deal C **Growth hormone for treating Turner syndrome in Canada: structuring evidence into the EVIDEM multi-criteria decision analysis framework to support decision making**

46

Tarride JE, Oremus M, Clayton N, Raina P **How does the Canadian general public view moderate Alzheimer's disease? Determination of health utility scores**

47

Tarride JE, Haq M, O'Reilly D, Xie F, Bowen J, Goeree R **The burden of obesity in adults living in Ontario**

48

Gladman DD, Psaradellis F, Martel MJ, Illouz O, Guerette B, Sampalis JS **Impact of adalimumab (HUMIRA®) on work productivity in patients with psoriatic arthritis: results from ACCLAIM**

49

Gladman DD, Sampalis JS, Martel MJ, Gooch KL, Wong RL, Guerette B **Reliability and validity of the Work Limitations Questionnaire in patients with psoriatic arthritis: results from ACCLAIM**

50

Guénette L, Gaudet M **Impact of prior authorization on the use of health services: a retrospective cohort study**

51

Redina T, Wakim R **Incidence and cost of cardiovascular co-morbidities in diabetic patients**

52

Bayoumi I, Holbrook A, Howard M, Schabert I **Interventions to improve medication reconciliation in primary care: a systematic review**

53

Gillman AF, Carter B **Large scale anonymized longitudinal patient data and its role in better understanding health care provider response to advisories**

54

Blais L, Beauchesne M-F, Lemièrre C, Perreault S, Forget A **New measures of patients' adherence and prescribing patterns: the case of adult patients with symptomatic persistent asthma**

55

Gagnon E **Pharmaceutical disposal programs for the public: a Canadian perspective**

56

Dolovich L, Gagnon A, McAiney CA, Sparrow L, Burns S **Pharmacists' perspectives and initial experience with the MedsCheck pharmacist medication review in Ontario**

57

Mendelssohn D, Lebner A, Soroka S, Cournoyer S, Da Roza G, Geary D, Beard K, Folia C, Ferreira L **Restricted access to drugs is associated with less optimal mineral metabolism control in hemodialysis patients**

58

Brassard P, Lowe A-M, Bernatsky S, Kezouh A, Suissa S **Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada**

59

Dragomir A, Angers J-F, Tarride J-E, Rouleau G, Drapeau P, Perreault S **Schizophrenia modeling: factors associated with the risk of being in a specific disease state**

60

Dragomir A, Angers J-F, Tarride J-E, Rouleau G, Drapeau P, Perreault S **Schizophrenia modeling: Markov model with Monte-Carlo microsimulation**

61

Leung VWY, Soon JA, Levine M, Lynd LD, Marra CA **Socioeconomic status of women obtaining emergency contraceptives from pharmacists in British Columbia**

62

Chin W, Andrew S **The cost-effectiveness of a blood test for colorectal cancer screening**

63

Sanyal C, Asbridge M, Kisely S, Andreou P, Sketris I **The determinants of benzodiazepine (BZD) use among individuals with major depressive episodes (MDE) in Canada**

64

Tsuyuki R, Beard K, Fitchett D, Jamal S, Lok C, Mendelssohn D **The effects of calcium-based vs. non calcium-based phosphate binders on outcomes among patients with chronic kidney disease: a meta-analysis**

65

Cyr M-C, Blais L, Beauchesne M-F, Lalonde L, Moisan J, Perreault S, Rahme E **The use of prescribed medications among residents of Quebec covered by a private drug insurance plan: results from the reMed pilot study**

66

Donnan J, MacDonald D, Collins K, El-Aneed A, Gladney N **Trends in the use of potentially harmful medications among seniors prior the implementation of a pharmacy network**

67

Lynd LD, Colley L, Guimarães C, Marra CA, Gill S, Simpson S, Meneilly G, Queiroz RHC **Using latent class analysis to model heterogeneity in patients' preferences for alternative routes of insulin delivery for diabetes management**

**We gratefully acknowledge sponsorship of the 2009 CAPT Conference
by the following donors:**

PLATINUM

**AstraZeneca
Merck Frosst Canada Ltd.**

GOLD

**CADTH
GlaxoSmithKline Inc.
Novo Nordisk Canada Inc.
Paladin Labs Inc.
Pfizer Canada Inc.
Rx&D
Sanofi-Aventis**

SILVER

**Amgen
Axia Research
Bayer Inc.
Brogan Inc.
i3 Innovus
Institute of Health Economics
Merck Frosst / Schering Pharma
Nycomed
Purdue**

BRONZE

**IMS Health
Lilly
Oxford Outcomes
PharmIdeas**